Trial · NCT03567473
Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study
NCT03567473, Phase 3, Completed, Children's Hospital of Eastern Ontario
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study. Trials, record NCT03567473. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03567473
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study
- NCT number
- NCT03567473
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 864 participants, actual
- Lead sponsor
- Children's Hospital of Eastern Ontario
- Conditions
- Bronchiolitis
- Interventions
- Oral dexamethasone, Nebulized Epinephrine, Oral placebo, Nebulized normal saline, MDI Epinephrine, MDI placebo
- First posted
- 2018-06-25
- Last updated
- 2025-07-28
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Admission to hospital for bronchiolitis within 7 days post enrollment | 7 days post enrollment | 1\) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
| Secondary | Admission to hospital for bronchiolitis at the time of the enrollment ED visit | Enrollment visit | 1\) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
| Secondary | All cause admission to Hospital within 21 days following enrollment ED visit | up to 21 days post enrollment | 1\) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
| Secondary | All cause Health care provider visits (including ED visits) by day 21 following enrollment ED | up to 21 days post enrollment | Visits to ED, other clinic, primary care provider, or any visit to see a nurse or physician following enrollment |
| Secondary | Health Care related costs within the 21 days following enrollment ED visits. | up to 21 days post enrollment | Health care related costs |
| Other | Safety outcome 1: Gastrointestinal bleeding | up to 21 days post enrollment | involving melena or frank blood per rectum (and not attributable to other causes, as determined by the treating physician) |
| Other | Safety outcome 2: Serious Bacterial Infection | up to 21 days post enrollment | meningitis, osteomyelitis or septicaemia |
| Other | Safety outcome 3: Severe Varicella | up to 21 days post enrollment | All of the following including: arthritis, osteomyelitis, symptomatic hepatitis, pancreatitis, cerebritis, pneumonitis, glomerulonephritis, disseminated intravascular coagulation, thrombo-cytopenia, prolonged vesicular rash (\<3 weeks), fasciitis, septicaemia, ocular complications, orchitis, myocarditis, intensive care admission and death |
| Other | Safety outcome 4: Death | up to 21 days post enrollment | Death |
| Other | Exploratory Outcome 1: Admission to hospital for bronchiolitis within 21 days following enrollment ED visit | up to 21 days post enrollment | 1\) Patient admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03567473
GET https://conductscience.org/api/trials/v1/NCT03567473/registered